All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Oncology Drugs in Phase I Clinical Development in FINLAND

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

TILT Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FINLAND Finland

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic

Contact the Supplier

Lead Product(s): TILT-123,Tumor infiltrating lymphocytes

Therapeutic Area: Oncology Product Name: TILT-123

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Lifeline Ventures

Deal Size: $6.9 million Upfront Cash: Undisclosed

Deal Type: Financing June 16, 2020

Details:

Funds will be used to advance TILT's proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials in Europe and the United States, and to prepare for Phase 2 trials.

TILT Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FINLAND Finland

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123

Contact the Supplier

Lead Product(s): TILT-123

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Biotheus

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 27, 2020

Details:

Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.